Ivo Grgic

📰 What makes Switzerland a leading hub for research and development in the life sciences?   Jérome Garcin, General Manager of BMS Switzerland, shares his perspective in the special Handelszeitung feature "20 CEOs – 20 Opinions."   He reflects on: 🔬 Switzerland’s role in advancing scientific innovation 🧬 Breakthroughs in oncology, cardiovascular, and neurological diseases 💊 How we can continue improving access to medicines for all patients   At BMS Switzerland, patients are at the center of every decision not just in words, but in practice. As Jérome Garcin explains in the interview, this means driving therapeutic innovation, accelerating access to life-saving treatments, and collaborating across disciplines to shape the future of medicine.   💡Read the full interview here: https://lnkd.in/eeMhPqXW Learn more about our work in Switzerland 👉 https://lnkd.in/dcZ794Hk #OneBMS #HandInHandForSwitzerland #BMSSwitzerland #Insight

126

3 Kommentare

Could Basel be the next Boston❓   When you think of biotech powerhouses, Boston or the Bay Area may come to mind. But the Basel Area in Switzerland is making a strong case to join that list.   Anchored by Roche and Novartis, the region now counts 800+ life sciences companies from global players like BeOne Medicines, Lonza, Basilea Pharmaceutica, Syngenta Group to startups pushing the frontiers of diagnostics, therapeutics, and manufacturing.   In this article, Fierce Biotech explores how the Basel Area is quietly but powerfully raising its game and how its Switzerland Innovation Park Basel Area is right at the heart of the story.   📰Read the full article: https://lnkd.in/g_XYQbWj #WhySwitzerland #LifeSciences Switzerland Innovation Swissnex swisstech Presence Switzerland Basel Area Business & Innovation Swiss Biotech Association Christof Kloepper Maximilien Murone Teresa Harris Graham David Veitch Adesh Kaul University of Basel Alentis Therapeutics Bright Peak Therapeutics Swiss Tropical and Public Health Institute Innosuisse Deep Tech Nation Switzerland SixPeaks Bio

600

18 Kommentare

As SFC Europe 2025 is in full swing in Basel, LCGC International spoke to John Reilly, Maria Kristina Parr, and Larry Miller about the important role that SFC now plays in life science analysis. Read the interview here: https://lnkd.in/gHh8X4xM

144

5 Kommentare

Today, we are proud to announce that Abacus Medicine Group has acquired Swiss Cardio Technologies AG. By joining forces, we will create better access to medicine. CEO Flemming Wagner says: “The opportunities for our two organisations are significant, and I look forward to exploring them together. The acquisition includes the global rights to our first pharmaceutical asset and is a strategic addition to the Abacus Medicine Group’s business model and our plans for continued profitable growth. It marks the beginning of a new chapter.” 

331

8 Kommentare

🔬 𝐎𝐩𝐭𝐢𝐦𝐢𝐬𝐢𝐧𝐠 𝐭𝐡𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐨𝐟 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐬𝐢𝐑𝐍𝐀 𝐚𝐧𝐝 𝐀𝐒𝐎𝐬 The pharmaceutical industry is entering a new era of precision medicine, with siRNA and antisense oligonucleotides offering promising strategies to modulate previously "undruggable" targets. However, their successful development requires overcoming unique translational and analytical challenges. This comprehensive white paper, authored by the IQ Consortium 𝑁𝑢𝑐𝑙𝑒𝑖𝑐 𝐴𝑐𝑖𝑑 𝑊𝑜𝑟𝑘𝑖𝑛𝑔 𝐺𝑟𝑜𝑢𝑝, consolidates cross-industry insights on best practices in ADME, tissue distribution, bioanalysis, and regulatory alignment for oligonucleotide-based therapies. 📌 𝐊𝐞𝐲 𝐚𝐫𝐞𝐚𝐬 𝐚𝐝𝐝𝐫𝐞𝐬𝐬𝐞𝐝 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: 🔗 𝐁𝐢𝐨𝐜𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐢𝐨𝐧 • GalNAc-conjugation remains the gold standard for hepatocyte targeting, but antibody-, lipid-, peptide-, and polymer-conjugates are expanding targeting options. • Conjugation enhances delivery but requires robust analytical and manufacturing strategies to ensure safety and scalability. 🧪 𝐁𝐢𝐨𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 • LC-MS is increasingly preferred for its specificity in quantifying oligonucleotides and metabolites. • SL RT-qPCR and LBA offer higher sensitivity but face challenges in specificity and regulated adoption. • A fit-for-purpose approach, aligning assay design with intended use, is critical. 🔄 𝐁𝐢𝐨𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 • Unlike small molecules, oligonucleotides are metabolised by nucleases, with metabolite profiles showing strong cross-species similarity. • Pharmacologically active metabolites (e.g., AS(n-1)3′) must be assessed to inform exposure–response relationships and mitigate safety risks. 📍 𝐓𝐢𝐬𝐬𝐮𝐞 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 • For GalNAc conjugates, predictable liver distribution allows for streamlined preclinical studies. • For novel modalities, radiolabeled studies (e.g., QWBA, SPECT) may still be needed to map biodistribution and inform first-in-human dose predictions. 📑 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 • Guidance remains limited and fragmented. • The IQ Consortium encourages a risk-based, platform-aware approach, leveraging established data packages for precedent chemistries and focusing resources on novel elements (e.g., linkers, conjugates). 🧠 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞-𝐀𝐰𝐚𝐲𝐬: • siRNA and ASOs require modality-specific approaches across bioanalysis, ADME, and PK/PD. • Bioconjugation strategies must balance targeting efficiency with manufacturability and safety. • LC-MS is increasingly central to oligonucleotide quantification, but hybrid platforms may be optimal. • Active metabolite profiling is essential, particularly for siRNA. • Regulatory flexibility exists, but proactive engagement and harmonisation are needed. #OligonucleotideTherapeutics #siRNA #ASO #Bioanalysis #TranslationalScience #ClinicalPharmacology #DrugDevelopment #PharmaceuticalInnovation #RegulatoryScience #ADME #IQConsortium

90

1 Kommentar

DINAMIQS, a Siegfried company, today inaugurated its state-of-the-art cGMP manufacturing facility for viral vectors — the first of its kind in Switzerland. The new facility enables end-to-end manufacturing of viral vector gene therapies, from molecule design to aseptic drug product filling. Read the media release: https://lnkd.in/eRgqbgpj

212

2 Kommentare